Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy entities : Ultragenyx pharmaceutical inc. save search
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Published: 2024-01-25 (Crawled : 21:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 0.55%
H: 1.01%
C: -1.16%
ux701 disease treatment therapy study
Gene Therapy Global Market is Projected to Grow at a CAGR of ~19% by 2028, Predicts DelveInsight
Published: 2024-01-12 (Crawled : 22:00) - prnewswire.com
TGTX | $14.25 1.06% 1.05% 3.2M
|
Health Technology
| Email alert
Add to watchlist
VRTX | $404.93 1.25% 1.43% 1.1M
|
Health Technology
| Email alert
Add to watchlist
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
| Email alert
Add to watchlist
SLDB | $9.08 0.44% 0.44% 300K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $95.11 6.88% 490
|
Health Technology
| Email alert
Add to watchlist
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
| Email alert
Add to watchlist
DTIL | $10.33 6.72% 6.29% 31K
|
Health Technology
| Email alert
Add to watchlist
global therapy market
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Published: 2023-07-31 (Crawled : 16:00) - biospace.com/
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 0.81%
H: 1.93%
C: -0.78%
ux701 disease treatment trial therapy
Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts
Published: 2023-06-21 (Crawled : 12:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: -0.04%
H: 4.07%
C: 4.07%
expansion therapy
Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit
Published: 2023-05-19 (Crawled : 12:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 0.63%
H: 1.69%
C: -2.62%
therapy
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
Published: 2023-05-08 (Crawled : 20:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: -1.57%
H: 2.42%
C: 1.64%
cell meeting therapy
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 1.85%
H: 1.0%
C: -3.43%
ABEO | News | $3.395 -53.87% -116.79% 5.5M
|
Health Technology
|
| O: 22.17%
H: 2.27%
C: -20.46%
abo-102 therapeutics therapy
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
Published: 2022-05-09 (Crawled : 13:00) - biospace.com/
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: -16.02%
H: 1.47%
C: -7.3%
therapy
Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III
Published: 2021-12-01 (Crawled : 15:00) - biospace.com/
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 0.25%
H: 3.1%
C: 0.98%
treatment disease phase 1 therapy
Ultragenyx Announces Additional Positive Multi-Year Durability Data from Phase 1/2 AAV Gene Therapy Studies
Published: 2021-11-29 (Crawled : 14:30) - biospace.com/
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 2.82%
H: 0.06%
C: -6.28%
gene therapy multi-year phase 1 positive therapy phase 2 phase 3
Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Published: 2021-10-18 (Crawled : 17:00) - biospace.com/
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: -1.4%
H: 0.27%
C: -1.09%
disease treatment gene therapy therapy trial
Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and ChildrenDojolvi is the only approved therapy for this rare, life-threatening metabolic disorder
Published: 2021-08-23 (Crawled : 13:00) - biospace.com/
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 4.68%
H: 4.22%
C: 4.04%
treatment brazil therapy metabolic children approval rare
Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow Healthcare Conference
Published: 2021-08-04 (Crawled : 13:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 0.1%
H: 5.22%
C: 1.91%
gene therapy therapy conference gene therapies
Ultragenyx Announces Positive Multi-Year Durability Data from Ongoing Phase 1/2 Gene Therapy Studies and Data on HeLa 3.0 Manufacturing Platform at American Society of Gene & Cell Therapy 2021 Annual Meeting
Published: 2021-05-14 (Crawled : 13:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 1.39%
H: 3.38%
C: 2.49%
ongoing phase 1 gene therapy positive therapy multi-year phase 3 phase 2 gene therapies
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting
Published: 2021-04-27 (Crawled : 22:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: -0.99%
H: 3.76%
C: 2.33%
presentation therapy
Ultragenyx Completes Successful End-of-Phase 2 Meeting with FDA and Finalizes Phase 3 Study Design for DTX301 Ornithine Transcarbamylase (OTC) Gene Therapy ProgramPhase 3 Study on Track to Initiate in Second Half 2021
Published: 2021-04-22 (Crawled : 14:00) - biospace.com/
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 0.39%
H: 2.14%
C: -0.64%
fda phase 2 gene therapy therapy phase 3 gene therapies designation
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson Disease
Published: 2021-01-21 (Crawled : 14:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: -2.58%
gene therapy therapy disease fda clearance fda drug new drug treatment gene therapies application clearance
Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies
Published: 2021-01-08 (Crawled : 14:03) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 0.03%
H: 5.3%
C: 3.53%
gene therapy positive therapy phase 3 phase 1 phase 2 gene therapies
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.